ECSP099778A - Dosis intravenosa y oral de un inhibidor p2y12 de acción directa y reversible - Google Patents
Dosis intravenosa y oral de un inhibidor p2y12 de acción directa y reversibleInfo
- Publication number
- ECSP099778A ECSP099778A EC2009009778A ECSP099778A ECSP099778A EC SP099778 A ECSP099778 A EC SP099778A EC 2009009778 A EC2009009778 A EC 2009009778A EC SP099778 A ECSP099778 A EC SP099778A EC SP099778 A ECSP099778 A EC SP099778A
- Authority
- EC
- Ecuador
- Prior art keywords
- intravenous
- inhibitor
- direct
- oral dose
- reversible action
- Prior art date
Links
- 230000002441 reversible effect Effects 0.000 title abstract 2
- 239000002172 P2Y12 inhibitor Substances 0.000 title 1
- 238000001990 intravenous administration Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001138 acetylsalicylic acid Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 229960000103 thrombolytic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91564907P | 2007-05-02 | 2007-05-02 | |
| US94792107P | 2007-07-03 | 2007-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP099778A true ECSP099778A (es) | 2010-01-29 |
Family
ID=39587015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2009009778A ECSP099778A (es) | 2007-05-02 | 2009-12-02 | Dosis intravenosa y oral de un inhibidor p2y12 de acción directa y reversible |
Country Status (17)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017402B1 (ru) * | 2005-11-03 | 2012-12-28 | Портола Фармасьютикалз, Инк. | [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение |
| BRPI0808422A2 (pt) * | 2007-03-06 | 2015-06-23 | Novartis Ag | Compostos orgânicos bicíclicos adequados para o tratamento de condições inflamatórias ou alérgicas |
| CN101720324A (zh) * | 2007-05-02 | 2010-06-02 | 波托拉医药品公司 | [4-(6-氟-7-甲基氨基-2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基)-苯基]-5-氯-噻吩-2-基-磺酰基脲盐、其相关的形式和方法 |
| US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| US9427448B2 (en) * | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| CN106075455A (zh) * | 2008-12-30 | 2016-11-09 | 丹麦国家医院 | 鉴定发展成器官功能衰竭的风险提高的危重患者的方法及用于其治疗的化合物 |
| US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| DK2498731T3 (da) | 2009-11-11 | 2020-03-02 | Chiesi Farm Spa | Fremgangsmåder til behandling eller forebyggelse af stenttrombose |
| CA2785487C (en) * | 2009-12-23 | 2017-11-28 | Ratiopharm Gmbh | Solid pharmaceutical dosage form of ticagrelor |
| US20130165459A1 (en) | 2010-01-12 | 2013-06-27 | Norvartis Pharma Ag | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
| WO2011137459A1 (en) * | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
| WO2012072743A1 (en) * | 2010-12-01 | 2012-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and kits for determining platelet susceptibility to activation in a patient |
| US8987285B2 (en) * | 2010-12-03 | 2015-03-24 | Portola Pharmaceuticals, Inc. | Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof |
| MX393334B (es) | 2017-03-15 | 2025-03-24 | Idorsia Pharmaceuticals Ltd | Administración subcutánea de un antagonista del receptor p2y12. |
| MA49452A (fr) | 2017-06-23 | 2021-05-05 | Chiesi Farm Spa | Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire |
| CN107462648B (zh) * | 2017-08-21 | 2019-09-27 | 盐城锦明药业有限公司 | 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| EA017402B1 (ru) | 2005-11-03 | 2012-12-28 | Портола Фармасьютикалз, Инк. | [4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины, их формы, способы получения соединений, фармацевтические композиции, содержащие эти соединения, и их применение |
-
2008
- 2008-05-02 WO PCT/US2008/062518 patent/WO2008137753A2/en not_active Ceased
- 2008-05-02 EA EA200901473A patent/EA200901473A1/ru unknown
- 2008-05-02 MX MX2009011843A patent/MX2009011843A/es not_active Application Discontinuation
- 2008-05-02 KR KR1020097025059A patent/KR20100029746A/ko not_active Withdrawn
- 2008-05-02 CA CA002686203A patent/CA2686203A1/en not_active Abandoned
- 2008-05-02 EP EP08747561A patent/EP2079464A2/en not_active Withdrawn
- 2008-05-02 AU AU2008247483A patent/AU2008247483A1/en not_active Abandoned
- 2008-05-02 BR BRPI0811476-5A2A patent/BRPI0811476A2/pt not_active IP Right Cessation
- 2008-05-02 US US12/114,630 patent/US20090048216A1/en not_active Abandoned
- 2008-05-02 CN CN200880023071A patent/CN101795682A/zh active Pending
- 2008-05-02 JP JP2010506688A patent/JP2010526101A/ja not_active Withdrawn
-
2009
- 2009-10-29 IL IL201834A patent/IL201834A0/en unknown
- 2009-10-30 TN TNP2009000451A patent/TN2009000451A1/fr unknown
- 2009-10-30 GT GT200900284A patent/GT200900284A/es unknown
- 2009-11-26 MA MA32377A patent/MA31663B1/fr unknown
- 2009-12-02 EC EC2009009778A patent/ECSP099778A/es unknown
- 2009-12-02 CO CO09137697A patent/CO6241104A2/es not_active Application Discontinuation
-
2011
- 2011-09-16 US US13/235,305 patent/US20120009172A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2079464A2 (en) | 2009-07-22 |
| IL201834A0 (en) | 2010-06-16 |
| KR20100029746A (ko) | 2010-03-17 |
| GT200900284A (es) | 2012-01-31 |
| CA2686203A1 (en) | 2008-11-13 |
| EA200901473A1 (ru) | 2010-06-30 |
| CO6241104A2 (es) | 2011-01-20 |
| BRPI0811476A2 (pt) | 2014-11-04 |
| US20090048216A1 (en) | 2009-02-19 |
| CN101795682A (zh) | 2010-08-04 |
| TN2009000451A1 (en) | 2011-03-31 |
| JP2010526101A (ja) | 2010-07-29 |
| WO2008137753A2 (en) | 2008-11-13 |
| AU2008247483A1 (en) | 2008-11-13 |
| MX2009011843A (es) | 2010-04-22 |
| WO2008137753A3 (en) | 2009-02-12 |
| MA31663B1 (fr) | 2010-09-01 |
| US20120009172A1 (en) | 2012-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP099778A (es) | Dosis intravenosa y oral de un inhibidor p2y12 de acción directa y reversible | |
| AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
| CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
| ECSP099376A (es) | Inhibidores de la actividad de la akt | |
| PL1986669T3 (pl) | Zastosowanie Bifidobacterium longum do zapobiegania i leczenia zapalenia | |
| BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
| ECSP077401A (es) | Medicamentos que contienen compuestos de carbonilo y su uso | |
| MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
| SV2009003335A (es) | Formulaciones para el cancer | |
| GT200900008A (es) | Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a | |
| CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| CL2014000297A1 (es) | Uso de un inhibidores de corrientes "funny" (if) o una de sus sales para utilizar en un metodo de tratamiento y prevencion de la insuficiencia cardiaca en felinos . | |
| NO20082120L (no) | Behandling og forebyggelse av mikroangiopati | |
| CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| UY35859A (es) | ?combinación farmacéutica que comprende amlodipina, losartán y rosuvastatina?. | |
| MX367209B (es) | Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación. | |
| HN2003000063A (es) | Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades. | |
| CO2017003263A2 (es) | Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer | |
| IT1398773B1 (it) | Sequenze oligonucleotidiche inibitrici dell'espressione della chimera ciclina d1/trop2 e loro uso in campo medico. | |
| MX2019003039A (es) | Forma de dosificacion de alivio prolongado. | |
| CY1116672T1 (el) | Χρηση αδαπαλενης και βενζοϋλυπεροξειδιου για την μακροχρονια αντιμετωπιση της κοινης ακμης | |
| CL2007002878A1 (es) | Agente farmaceutico que comprende 1) un inhibidor de her2 que tiene un esqueleto de pirrolopirimidina o de pirazolopirimidina y 2) un agente terapeutico hormonal o anticancerigeno en combinacion; y uso pra la prevencion o el tratamiento del cancer. |